Maturitas
Volume 55 , Pages S47-S54 , 1 November 2006

Premenstrual syndrome: From etiology to treatment

References 

  1. O’Brien PM, Chenoy R. Premenstrual syndrome. In:  Shaw RW,  Soutter WP,  Stanton SL editor. Gynecology. 2nd ed.. Edinburgh: Churchill Livingstone; 1993;p. 359–372
  2. Kraemer GR, Kraemer RR. Premenstrual syndrome: diagnosis and treatment experiences. J Women Health. 1998;7(7):893–907
  3. Reid R. Premenstrual syndrome. N Engl J Med. 1991;324:1208–1210
  4. ACOG (American College of Obstetricians and Gynecologist). Premenstrual syndrome. ACOG Practice Bulletin; 15 April 2000.
  5. Borenstein J, Chigo CF, Dean D, et al. Estimating direct and indirect costs of premenopausal syndrome. J Occup Environ Med. 2005;47(1):26–33
  6. APA (American Psychiatric Association) . Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association; 1994;p. 715–8
  7. Mortola J. Premenstrual syndrome pathophysiologic considerations. N Eng J Med. 1998;338:256–257
  8. Singh B, Berman B, Simpson R, et al. Incidence of premenstrual syndrome and remedy usage: a national probability sample study. Altern Ther Health Med. 1998;4:75–79
  9. Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system clinical implications. Ann Intern Med. 1998;129:229–240
  10. Backstrom T, Andrean L, Birzniere V, et al. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs. 2003;17(5):325–342
  11. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology. 2003;28:39–53
  12. Rubinow DR, Hoban MC, Grover GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related disorder and in control subjects. Am J Obstet Gynecol. 1998;158:5–11
  13. Waytt K, Dimmock P, Jones P, et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systemic reviews. BMJ. 2001;323(6):776–780
  14. Backstrom T. Neuroendocrinology of premenstrual syndrome. Clin Obstet Gynecol. 1992;35(3):612–628
  15. Spence KT, Plata-Salaman CR, French-Mullen JM. The neurosteroids pregnenolone and pregnenolone-sulfate but not progesterone, block Ca2+ currents in acutely isolated hippocampal CA1 neurons. Life Sci. 1991;49(26):PL235–PL239
  16. Monteleone P, Luisi S, Tonetti A, et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol. 2000;142(3):269–273
  17. Gruber CJ, Huber JC. Differential effects of progestins on the brain. Maturitas. 2003;46(Suppl. 1):S71–S75
  18. Nyberg S, Andersen A, Zingmark E, et al. The effect of low dose of alcohol on allopregenenolone serum concentrations across the menstrual cycle in women with severe premenstrual syndrome and controls. Psychoneuroendocrinology. 2005;January 23: Epub ahead of print
  19. Perry DL, Miles D, Borruss K, et al. Premenstrual symptomatology and alcohol consumption in college women. J Stud Alcohol. 2004;65(4):464–468
  20. Peters F. Clinical significance of serum prolactin levels in cyclic mastalgia. In:  Peters F editors. An update of cyclic mastalgia. New Jersey: Parthenon Publishing Group; 1988;p. 31–34
  21. Kubista E. Cyclic mastalgia-disease or not disease. In:  Peters F editors. An update of cyclic mastalgia. New Jersey: Parthenon Publishing Group; 1988;p. 11–15
  22. Wuttke W, Splitt G, Gorkow C, et al. Behandlung zyklusabhaengiger Brustschmerzen mit einem Agnus castus-haltingen Arzneimittel-Ergebnisse einer randomisierten, plazebokontrollen Doppelblindstudie. Geburts und Frauenheilk. 1997;57:569–574
  23. Jarry H, Leonhardt S, Wuttke W, et al. Auf der Suche nach dopaminergen Substanzen in Agni-cast-fructus-Praeparaten: Warum eigentlich?. Zeithschrift fuer Phytotherapie. 1999;20:150–152
  24. Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus castus)—pharmacology and clinical indications. Phytomedicine. 2003;10:348–357
  25. Milewicz A. Clinical aspects of breast benign disease. Polish J Endocrinol. 1997;2(48):51–57Suppl. 1
  26. Milewicz A, Bednarek-Tupikowska G, Szymczak J, et al. Therapeutic affect of bromocriptine on patients with benign breast disease. In:  Genazzani AR,  Pertaglia F,  Volpe A,  Facchinetti F editor. Recent research on gynecological endocrinology. vol. 1:Lancs, NJ: The Parthenon Publishing Group; 1988;p. 647–652
  27. Milewicz A, Gejdel E, Sworen H, et al. Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Drug Res. 1993;43(7):752–756
  28. Ashby CR, Carr LA, Cook CL, et al. Alteration of platelet serotoninergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry. 1988;24:225–233
  29. Biegon A, Mc Ewen BS. Modulation be estradiol of serotonin receptors in brain. J Neurosci. 1982;2:199–205
  30. Levin AM. Pre-menstrual syndrome: a new concept in its pathogenesis and treatment. Med Hypotheses. 2004;62:130–132
  31. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drosperinone, a new progestagen. Contraception. 2000;61:105–111
  32. Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol. 2003;188(5):56–65
  33. Masho SW, Adera T, South-Paul J. Obesity as a risk factor for premenstrual syndrome. J Psychosom Obstet Gynecol. 2005;26(1):33–39
  34. Trout KK, Teff KL. Insulin sensitivity and premenstrual syndrome Eur. Arch Psychiatry Clin Neurosci. 2004;254(5):326–329
  35. Rose DP, Boyar AP, Cohen C, et al. Effect of low-fat diet on hormone levels in women with cystic breast disease. J Natl Cancer Inst. 1987;78:623–626
  36. Bertone-Johnson ER, Haakinson SE, Bendich A. Calcium and Vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med. 2005;165(11):1246–1252
  37. Bianchi-Demicheli F, Ludicke F, Lucus H, et al. Premenstrual dysphoric disorder: current status of treatment. Swiss Med Wkly. 2002;123(39–40):574–578
  38. Skałba P. Menstrual disturbances. In:  Skałba P editors. Gynecological endocrinology. Wydawnictwo Lekarskie PZWL; 1998;p. 236–277
  39. Freeman EW, Sammel MD, Rinaudo PJ, et al. Premenstrual syndrome as predictor of menopausal symptoms. Obstet Gynecol. 2004;103(5, Part 1):960–966
  40. Mortola JF, Girton L, Beck L, et al. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol. 1990;76(2):302–307
  41. Andrus GM. Recent and future advances in the treatment of PMS, PMDD and menopause. Drugs. 2001;4(120):1341–1373
  42. Milewicz A, Demissie M, Jedrzejuk D, et al. Secondary amennorhea, diagnostic and therapy. An attempt to create the standard. Adv Clin Exp Med. 2004;13(1):135–139
  43. Kilicdag EB, Tarim E, Bagis T, et al. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. Int J Obstet Gynecol. 2004;85:292–293
  44. Barnes J, Ernst E. Traditional herbalists prescriptions for common clinical conditions: a survey of members of the UK National Institute of Medical Herbalists. Phytother Res. 1998;12:369–371
  45. Wyatt KM, Dimmock PW, Fischer M, et al. Prescribing patterns in premenstrual syndrome. BMC Women's Health. 2002;2(4):1–8
  46. Tesch BJ. Herbs commonly used by women. An evidence-based review. Am J Obstet Gynecol. 2003;188(5):44–55
  47. Mayo J. Premenstrual syndrome. A natural approach to management. Clin Nutr Insights. 1997;5:1–8
  48. Jarry H, Spengler B, Porzel A, et al. Evidence for estrogen receptor beta-selective activity of Vitex agnus castus and isolated flavones. Planta Med. 2003;69:945–947
  49. Blumenthal M, Busse W, Goldberg A, et al. The complete German Commission E monographs: therapeutic guide to herbal medicines. Austin, TX: American Botanical Council; 1998;p. 1694
  50. Ditrmar F, Bohnert KJ, Peeyters M, et al. Premenstrual syndrome: treatment with a phytopharmaceutical. Therapiewoche Gynekol. 1992;5:60–68
  51. Wyatt K, Dimmock P, Jones P, et al. Efficacy of progesterone and progestagens in management of premenstrual syndrome: systemic review. BMJ. 2001;323:776–780
  52. Dimmock PW, Wyatt K, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome, a systematic review. Lancet. 2000;365(9236):1131–1136
  53. Pearlstein TB, Halbreich U, Batzar FD, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with Sertraline or placebo. J Clin Psychiatry. 2000;61:101–109
  54. Freeman EW. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs. 2004;18(7):453–468
  55. Parsey KS, Pong A. An open-label, multicenter study to evaluate yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61:105–111

PII: S0378-5122(06)00238-6

doi: 10.1016/j.maturitas.2006.06.016

Maturitas
Volume 55 , Pages S47-S54 , 1 November 2006

Article Tools